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Abstract
Background: In 2008, the IAS-USA published the revised guidelines for the use of HAART in adults substantially increasing
the number of individuals eligible for HAART. The epidemic in British Columbia (BC) is mainly among men who have sex
with men and those with injection drug use. Here, we explored the potential impact of different HAART coverage scenarios,
based on the new guidelines, on the HIV-related incidence, morbidity and mortality in BC, Canada.
Methodology: We built a mathematical transmission model to investigate different HAART coverage scenarios (50%,
60%, 75% and 100%) of those medically eligible to receive HAART under the 2008 IAS guidelines. All new scenarios
were compared to the current coverage in BC under the 2006 IAS guidelines (i.e. baseline scenario). In BC, it is
estimated that 25–30% of individuals are unaware of their status. Costs were drug-related and reported in Canadian
dollars. HIV-related morbidity and mortality were estimated based on the disability-adjusted life years (DALY)
methodology.
Principal Findings: Currently, there are 4379 individuals on HAART under the IAS 2006 guidelines and 6781 individuals who
qualify for treatment based on the new guidelines. Within 5 years, increasing HAART coverage decreased yearly new
infections by at least 44.8%. In the 50% scenario, in 5 years, DALY decreased by 53% corresponding to 4155 averted DALYs,
and in 25 years it decreased by 66% corresponding to 5837 averted DALYs. The effect was even stronger if the 75% scenario
was chosen instead. Compared to the 100% expansion scenario, we observed an excess in annual direct treatment
expenditures at the end of 5 years of approximately 1 million dollars in the 75% scenario, and of approximately 2 million
dollars in the 50% scenario.
Conclusions/Significance: The individual and public health benefits of these new guidelines are immense. The results show
that by increasing the number of individuals on HAART save lives, it is cost averting, and it positively impacts society by
decreasing the number of new HIV infections. Thus, public health community should consider incremental gains when
considering guidelines and policy.
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Introduction
At the end of 2008, after almost three decades since AIDS was
first identified, neither a cure nor a fully preventive vaccine is
available [1–4]. Despite multiple efforts, the epidemic remains an
exceptional challenge. It is estimated that, in 2008, 33 million
individuals are living with HIV/AIDS in the world, 2.7 million
(range 2.2–3.2million) became HIV infected and 2 million (range
1.8–2.3 million) died from AIDS-related causes [5]. Despite
substantial prevention efforts and increases in antiretroviral
therapy roll-out programs, the epidemic continues its relentless
pace. The ability to control HIV/AIDS morbidity and mortality,
as well as the spread of HIV has been further compromised as a
result of the worldwide financial crisis [6,7].
It is increasingly apparent that a targeted combination of
proven effective interventions will be necessary if we are going to
have a chance to control the impact of HIV/AIDS [8–12].
Expanding access to antiretroviral treatment to those in medical
need has been proposed as a key component of the above
mentioned combination prevention approach [8–12]. In brief,
highly active antiretroviral therapy (HAART) decreases plasma
HIV-1-RNA levels to undetectable levels of currently available
assays (i.e. ,50 copies/mL) in a sustained and reliable fashion.
This leads to a dramatic decrease in HIV-1-RNA in sexual
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secretions (including semen, vaginal fluids and rectal mucosa),
which in turn is associated with substantial decrease in the risk of
HIV transmission. This effect has now been documented in
mother-to-child transmission studies, as well as in observational
studies involving discordant heterosexual couples and population-
based cohorts [13–20]. More recently, further supportive evidence
derived from a longitudinal study of injection drug users was
presented, where ‘‘community’’ HIV-1-RNA level was found to be
the strongest predictor of HIV incidence even after adjusting for
traditional risk factors including needle sharing and high-risk sex
[19]. Not surprisingly, ‘‘community’’ HIV-1-RNA level in this
study was inversely correlated with the use of HAART.
HIV/AIDS related morbidity and mortality have decreased
dramatically with the widespread availability of HAART [21–23].
Today, HIV/AIDS is seen as a chronic and manageable condition
with continued use of HAART, even in resource-limited settings as
a result of the relentless roll-out of antiretroviral therapy [24].
Sadly, however, access to HAART remains a challenge through-
out the world, even within resource-rich regions [25–28]. Egger et
al. [25], using data from 42 resource-limited and resource-rich
countries (total of 33008 individuals), has shown that in the vast
majority of countries the median CD4 cell count at the time of
initiation of HAART is substantially below 200 cells/mm3. At
such a level, the risk of disease progression or death is only
partially reversed by HAART [8,26].
Even in British Columbia (BC), Canada, where there is a
universal health care system that provides medical services,
including laboratory monitoring, care and antiretroviral therapy
free of cost, it has been shown that late or no access to care are
major determinants of HIV/AIDS-related mortality [28]. In BC,
this tends to be particularly prevalent among rural and urban
aboriginal populations, female sex-trade workers, street-involved
youth, immigrants from HIV-endemic countries, younger men
who have sex with men, as well as among the poor, the homeless
and those with mental health and addiction challenges, also
referred to as hard-to-reach population [29–31]. Here and abroad,
the health system has been slow to recognize that facilitated and
supported access to care represents a cost-effective means of
enhancing HIV/AIDS control, as it relates to HIV/AIDS-related
morbidity and mortality as well as HIV transmission.
Recently, the International AIDS Society-USA (IAS-USA)
updated the guidelines for the use of HAART in adults infected
with HIV [8]. In brief, the 2008 IAS-USA guidelines substantially
expanded eligibility to HAART as it recommended that HAART
should be offered to all symptomatic HIV infected individuals and
to those who are asymptomatic but have CD4 cell counts below
350 cells/mm3. Furthermore, according to the 2008 IAS-USA
guidelines, HAART should be offered to all asymptomatic
individuals regardless of CD4 cell count if they are at high risk
for short-term progression of their disease, as demonstrated by a
plasma HIV-1-RNA level above 100,000 copies/mL or an
absolute CD4 cell count decrease greater than 100 cells/mm3
within a year. Finally, for the first time based on the new
understanding of HIV infection as a chronic inflammatory disease,
the 2008 IAS-USA guidelines recommend that HAART should
also be offered to all asymptomatic individuals regardless of CD4
cell count if they have an underlying condition or morbidity risk
that will be aggravated by untreated HIV infection or that will
compromise their future treatment options. Most prevalent among
these are history of cardiovascular disease or increased cardiovas-
cular risk, HIV-associated nephropathy, and chronic active
hepatitis B or C. Similar recommendations have now been put
forward in the USA and in Europe [32–33]. Based on these
guidelines changes, the number of individuals eligible for HAART
has increased substantially. However, no estimates are available
regarding the potential impact that the implementation of the
2008 IAS-USA guidelines might have on HIV/AIDS related
morbidity and mortality and on HIV transmission in a given
population.
Therefore, we undertook the present study to estimate the
potential impact of the 2008 IAS-USA guidelines on HIV/AIDS
related morbidity and mortality and HIV transmission in BC, via a
deterministic mathematical model, in the next 5 (short-term) and
40 (long-term) years, under different HAART expansion scenarios.
We decided to focus on the impact of the new guidelines in BC,
given that it houses the British Columbia Centre for Excellence in
HIV/AIDS, which has been instrumental in the concept of
HAART expansion as a powerful way to curb the HIV epidemic.
Methods
Incidence estimates
The BC Centre for Disease Control (BCCDC) produces an
annual HIV/AIDS Update report, which includes the number of
persons testing newly positive for HIV by year of testing since
1985. Since the year 2000, the number of new positive tests has
been relatively stable at approximately 400 cases per year [34,35].
Additionally, the Public Health Agency of Canada (PHAC)
estimates that 30% of those newly infected are not aware of their
status, and that HIV incidence in BC is around 340 to 670 new
cases per year [36]. Therefore, based on the BCCDC and PHAC
estimates, we used the number of positive tests as a proxy for the
number of new HIV cases per year.
Target Population
In BC, at the end of 2005, PHAC estimated that 12300
individuals were infected with HIV [37]. The epidemic affects
predominantly men who have sex with men (MSM), followed by
injection drug users (IDUs), and heterosexual/non-endemic
contacts [36]. Among those infected with HIV, it is estimated
that 7380 persons are engaged in care and 4920 are not engaged
(i.e. hard-to-reach population [see Introduction for description]).
We assumed the same age distribution of those $20 years who
tested newly positive for HIV in 2006 (N = 393) as reported by the
BCCDC, i.e. 94 (24%) in the group 20–29 years, 124 (32%) in the
group 30–39 years, 107 (27%) in the group 40–49 years, and 68
(17%) in the 50+ years group [34,35]. The mortality distribution of
our target population in 2006 was obtained from the BC Centre
for Excellence in HIV/AIDS Drug Treatment Program, and the
overall BC population mortality estimates were obtained from the
CANSIM tables from Statistics Canada [38]. To maintain
consistency, in all analyses involving age distribution, we used
the same age groups as defined in the BCCDC reports. The data
in the model consider that between 25% to 30% of individuals are
unknow of their HIV status. Also, HIV testing in the province is
done solely, free-of-cost, by the BCCDC to all residents in the
province, and the numbers increased from 160,554 tests at the end
of 2005 to 182,151 tests at the end of 2008, however, for the model
purpose we did not include as a separate parameter the number of
HIV tests done in the province by BCCDC.The Centre’s HIV/
AIDS Drug Treatment program has received ethical approval
from the University of British Columbia Ethics Review Committee
at its St. Paul’s Hospital site. The program also conforms with the
province’s Freedom of Information and Protection of Privacy Act.
Model Structure
We built a deterministic transmission model based on the
different disease stages of the HIV-1 natural history, whereby high
HAART Impact on HIV Incidence
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plasma HIV-1-RNA levels being associated with higher chance of
disease transmission (Figure 1). The model takes into consideration
HIV transmission from those at risk in the main transmission
groups in BC (men who have sex with men, injection drug use and
female sex workers). We have not included transmissions from
heterosexual contact given that this mode of transmission is not the
driver of the BC epidemic and that limited data are available to
calibrate the necessary parameters associated with this epidemic.
The model characterizes the natural history of HIV by three
infectivity periods: susceptible; early phase (plasma HIV-1-RNA
load ,3; $3 and ,4; $4 log10 copies/mL); and late stage (CD4
cell count ,200 cells/mm3). These different transmissions groups
were chosen to illustrate that during early phase high viral load is
likely to be the main determinant of HIV transmission, and during
late phase CD4 cell count plays an additional role in HIV
transmission given that in this stage individuals are more likely to
develop opportunistic infections. At any of these infectivity
periods, we considered death as a possible outcome. The model
considers all eligibility criteria for starting therapy as described in
the 2008 IAS-USA treatment guidelines [8]. For the analyses
presented here, we refer to the IAS-USA guidelines before the year
2008 as the Status Quo scenario. Note that the BC Centre for
Excellence is moving away from the Status Quo scenario and
adopting the new guidelines. Given the economic crisis and the
provincial budget for HIV/AIDS, there was a need to estimate
patient and societal benefits based on different HAART expansion
scenarios.
The model was updated every month since therapy initiation,
and run for 40 years. At each interaction, we generated the
number of new infections, the number of individuals eligible for
treatment, the number of individuals waiting for treatment and the
number of deaths. The model in Figure 1 is specified by four
ordinary differential equations:
dS
dt
~p{S| m1zl tð Þð Þ
dW
dt
~S|l tð Þ{W| czm2zqð Þ
dU
dt
~W|q{U| w tð Þzm4ð Þ
dT
dt
~W|czU|w tð Þ{T|m3
where S: Susceptible and at risk; W : Infected and waiting to meet
eligibility to start treatment; U : Infected, eligible, but not on
treatment; T : Infected, eligible and on treatment; and N, the total
population, being defined as N~SzWzTzU . The definitions
of the parameters in these four differential equations are presented
in Table S1.
As shown in Figure S1, we stratified the HIV infected
population in BC based on access to care and eligibility for
HAART as: (1) individuals currently receiving HIV treatment and
care (N = 4379); (2) individuals who are currently engaged in care,
who now meet HAART eligibility criteria under the new
guidelines (N = 1602); (3) same as group 2, but despite being well
adjusted, decline initiation of treatment (N = 600); (4) individuals
who are currently engaged in care, but yet do not meet HAART
eligibility criteriae (N = 798); (5) individuals not engaged in care,
who should have been on treatment under the previous guidelines
because their CD4 cell count is #200 cells/mm3; (6) and (7)
individuals not engaged in care, who now meet the eligibility to
start HAART under the new guidelines because their CD4 cell
count is #350 cells/mm3 (N = 1036) or because they meet at least
one of the other criteria for therapy initiation (N = 1476),
respectively ; and (8) individuals who are not engaged in care,
and do not meet the HAART eligibility criteria (N = 342) .We
investigated four scenarios of HAART coverage: 50%, 60%, 75%
and 100% of all individuals in groups 2, 3, 5, 6 and 7.
The model assumptions were calibrated and validated using the
number of individuals testing newly positive for HIV obtained
from the BCCDC, and the number of patients enrolled in the
Centre’s Drug Treatment Program from January of 2006 until the
end June of 2008.This model was implemented in Berkeley
Madonna Inc. version 8.3.11.
Cost Estimates
Direct costs were based on treating an individual with first-line
therapy in BC during a full year (CAN$ 15800 per year), and no
correction was made regarding inflation or discounting (source:
Pharmacare, BC Ministry of Health Services). This cost does not
include full patient costs or societal costs. An extensive economic
evaluation is underway to address both of these previous costs. The
lifetime cost was based on a life expectancy of 28.1 years at the age
of 20 years in 2006 using the same methodology as in Hogg et al.
[22]. Note that different CD4 cell strata might have different life
expectancies, but given that the model focused on classifying
individuals by different viral load and not CD4 cell count strata,
we decided to use the number 28.1 years uniformly across all CD4
cell strata. However, the mortality rates were adjusted for different
age groups and model strata.
Burden of Disease
We used the World Health Organization (WHO) Global
Burden of Disease study methodology to assess the impact of
disease on the quality of life of the population as a whole [39]. In
brief, this approach combines estimates of mortality and morbidity
for populations into a single measure of disease burden called
disability-adjusted life years (DALY). DALYs are used as a
Figure 1. Transmission Model. This diagram shows the distribution
of the population at a given point in time. The arrows indicate the
movement of individuals across infectivity strata. Parameters’ explana-
tion and value are displayed in Table S1.
doi:10.1371/journal.pone.0010991.g001
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summary measure of population health that reflects the impact of
both mortality and non-fatal health decrements. DALYs quantify
the gap in years between age at death and some standard age
before which death is considered ‘‘premature’’ in addition to time
lived in states other than excellent health. DALYs are obtained by
summing years of life lost (YLL) from premature death and
healthy years lost due to disability (YLD). The key assumptions
and decisions made with respect to the estimation of DALY
parameters are as follows: a discounting future health rate equal to
3%; age weighting was not utilized; and life long durations were
based on the time HIV-positive individuals in BC are expected to
live once infected, and calculated using the methodology in Hogg
et al. [22] After combining the results for the estimated number of
new infections (Itj) and deaths (NDtj) for each year t (t= 1,…,40) and
age group j (j= 20–29, 30–39, 40–49, 50+), the corresponding
YLD and YLL estimates for HIV in BC were derived as:
YLDtj~Itj|DWj|
1
0:03
| 1{exp {0:03|Dj
  
YLLtj~NDtj|
1
0:03
| 1{exp {0:03|Lj
  
where DWj represents the disability weight for HIV cases (0.135
for those $20 years old39); Dj represents the average duration of
disability estimated to be 28.1, 25.3, 21.8, 18.2 years for j= 20–29,
30–39, 40–49, 50+, respectively; and Lj represents the life
expectancy and estimated to be 78.8, 69.3, 59.8, 50.9 years for
j= 20–29, 30–39, 40–49, 50+, respectively, for the jth age group.
Therefore the DALY estimate, for the jth age group, and the tth
year, was derived as:
DALYtj~YLDtjzYLLtj
Results
Using data of 12300 individuals infected with HIV, we were
able to estimate the impact of HAART expansion and of the 2008
IAS-USA guidelines on the epidemic in BC. Thus in the short-
term (i.e. 5 years), comparing the Status Quo scenario to the 50%,
60%, 75% and 100% HAART expansion based on the 2008 IAS-
USA guidelines scenarios, the model estimated that by increasing
the number of eligible individuals on treatment by 50%, the total
averted infections was 1360 (percent decrease 45%) and in the
100% scenario this number increased to 1498 (percent decrease
49%) averted new infections (Table 1). Table 1 also presents the
avoided direct costs associated with each of these scenarios. The
50% scenario generated approximately CAN$ 21.5 million in cost
savings, and if the expansion reached a 100% of those in medical
need, this figure was increased by approximately CAN$ 2.2 million
in just 5 years.
From this point forward, we will compare the 50% and 75%
expansion scenarios, as they are practical achievable targets.
Figure 2 presents the cumulative number of new infections averted
and associated lifetime avoided costs for the 50% and 75%
HAART expansion based on the 2008 IAS-USA guidelines
scenarios. By enrolling an additional 50% of eligible individuals to
HAART, 11387 new HIV infections were averted in 40 years,
which is the equivalent of $4.2 billion in avoided HIV lifetime
treatment costs that would have been incurred if these individuals
had become infected. If this coverage was increased to 75%, we
estimated that 14911 new HIV infections were averted in 40 years,
which is the equivalent of $5.6 billion in avoided HIV lifetime
treatment costs.
The model predicted that in BC, in the next 5 years, if nothing
is changed, individuals would loose 6819 years due to premature
death (YLL), 1005 healthy years due to disability (YLD) and 7824
DALYs, and the DALYs continue to increase as times passes by,
reaching 8891 in 25 years (14% increase) (Table 2). If the HAART
expansion based on the 2008 IAS-USA guidelines 50% scenario is
achieved, in 5 years DALY decreases by 53% corresponding to
4155 averted DALYs, and in 25 years it decreases by 66%
corresponding to 5837 averted DALYs. Table 2 shows the effect is
even stronger if the 75% HAART expansion based on the 2008
IAS-USA guidelines scenario is achieved instead.
Given that HAART expansion based on the 2008 IAS-USA
guidelines will require significant investments, it is important to
also look at the return on increase investment as a result of the
HAART expansion initiative. We achieved this by plotting the
projected annual HIV drug treatment cost over 40 years as per the
Status Quo, versus the projected annual HIV drug treatment cost
based on the proposed implementation of HAART expansion
based on the 2008 IAS-USA guidelines for the 50% and 75%
scenarios (Figure 3). We estimated that after 20 years, the 50%
scenario will yield high returns, and this period is shortened by 5
years if expansion is done based on the 75% scenario.
Discussion
Our results demonstrated that HAART expansion to those in
need, based on the 2008 IAS-USA guidelines in British
Columbia, will be expected to result in an immediate decrease
in HIV/AIDS morbidity and mortality and a decrease in HIV
Table 1. Effect of HAART expansion on the projected number of new HIV infections and HIV infections averted in the next 5 years,
by different scenarios.
IAS-USA
Therapeutic
Guidelines
HAART
expansion
scenario
Total number
of new infections
in 5 years
Averted
new infections
in 5 years
Percent decrease
in new infections
in 5 years
5-year Cost
Avoidance
(Can$)
Lifetime Cost
Avoidance
(Can$)
2006 None 3,037 0 0 0 0
2008 100% 1,539 1,498 49.3 $23,668,400 $428,398,040
75% 1,608 1,429 47.1 $22,578,200 $634,447,420
60% 1,650 1,387 45.7 $21,914,600 $615,800,260
50% 1,677 1,360 44.8 $21,488,000 $603,812,800
doi:10.1371/journal.pone.0010991.t001
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incidence. Indeed, we showed that in 5 years, we could avert at
least 1360 infections, avert loosing 4155 years due to disability
and mortality and approximately CAD$ 21 million in averted
costs by just increasing HAART coverage to 50% of eligible
individuals. The benefits were even bigger is expansion is done
for the 75% scenario, instead. The averted lifelong costs
associated with the initiative were also significant, and the timing
for the return of investment was directly and strongly associated
with how many more patients will be coved by HAART
expansion. However, despite of costs associated with this
initiative, we have shown that there will be huge gains in healthy
years and in decreasing premature mortality of those infected
with HIV in the short and long terms.
However, there are tremendous challenges associated with this
initiative, given that a substantial number of individuals eligible
for treatment will come from the pool of those marginalized and
not engaged in care. The HAART expansion based on the 2008
IAS-USA guidelines will therefore require the development of a
sustained and intensified strategy to identify HIV infected
individuals and those at risk, helping them to stabilize their lives
and facilitate their sustained engagement in appropriate health
care and support, all of this within a voluntary and fully
consented framework. These individuals are usually suffering
from mental illnesses, addiction and poverty, thus complicating
their access to proper health care, as it is the case of a large
number of Aboriginal peoples and injection drug users. Of note,
the estimated 25%–30% of HIV-infected individuals who are
unaware of their HIV status represents a major unresolved
challenge. Further focused efforts are underway to conduct
feasibility studies to massively test individuals to address this
deficit, and provide valuable data for other HAART expansion
programs [40]. Additionally, it is worthy mentioned that this
model was based on the epidemic in BC, which is concentrated
among MSMs and IDUs, which is the opposite of other parts of
the world which have generalized epidemics, and therefore the
results of this model should be taken cautiously. Another model
limitation, which directly affects the HAART expansion initia-
tive, is the fact that we did not account for loss of follow-up.
There is work under way to estimate in our program what is the
Figure 2. Comparison of the projected number of new HIV infections: Status Quo approach versus 50% and 75% expansion
scenarios (over 40 years).
doi:10.1371/journal.pone.0010991.g002
Table 2. Burden of Disease of Status Quo and 50% and 75%
HAART expansion scenarios.
Scenario YLL YLD DALY YLD/YLL DALYs Averted
Status Quo
5 years 6,819 1,005 7,824 0.147
10 years 7,114 1,017 8,132 0.143
15 years 7,402 1,033 8,435 0.140
25 years 7,834 1,057 8,891 0.135
HAART Expansion 50%
5 years 3,146 523 3,669 0.166 4,155
10 years 3,087 450 3,536 0.146 4,595
15 years 2,982 410 3,393 0.138 5,042
25 years 2,722 332 3,054 0.122 5,837
HAART Expansion 75%
5 years 1,882 295 2,176 0.157 5,647
10 years 1,779 148 1,926 0.083 6,205
15 years 1,699 140 1,840 0.083 6,595
25 years 1,585 136 1,721 0.086 7,170
YLL: years of life lost; YLD: healthy years lost due to disability; DALY: disability-
adjusted life years; DALY averted, for a given year, was calculated in reference
to the Status Quo scenario.
doi:10.1371/journal.pone.0010991.t002
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percentage of individuals lost to follow-up, how much such
percentage might change over time, and its impact on
population-level viremia. Finally, the proposed HAART expan-
sion based on the 2008 IAS-USA guidelines should take place
within a concerted effort to strengthen other evidence based
preventive interventions, including education, risk reduction and
harm reduction strategies [41–43].
To date, HAART has dramatically decreased morbidity and
mortality among HIV infected individuals around the world.
HAART expansion based on the 2008 IAS-USA guidelines has a
tremendous potential to further improve health outcomes among
HIV infected individuals in BC and in the rest of the world and,
furthermore, to substantially change the course of the HIV
epidemic by decreasing rates of HIV transmission, tuberculosis,
malaria and other infectious diseases and therefore curbing the
growth of the epidemic [41]. However, all these benefits come
with a high price. The best tolerated and efficient antiretroviral
drugs are still quite expensive and unaffordable in parts of the
world, and sometimes have unwanted side effects such as
antiretroviral resistance. Recently there was a mathematical
model that showed that drug resistance can pose a threat to
expansion HAART initiatives [44]. Yet, our group has empir-
ically shown that population-level drug resistance has been
declining in BC since 1996, due to an increasing number of
individuals achieving virologic suppression in our program, and
therefore we believe that drug resistance in settings like ours
might not pose any threat to an increased number of individuals
receiving HIV care [45]. In addition, delivering proper care to all
of those who meet medical eligibility criteria will require
substantial efforts from public and private sectors, and the urgent
address of underlying systemic challenges such as stigma,
discrimination, inadequate healthcare infrastructure, lack of
education, poor nutrition, homelessness, insufficient mental
health services, lack of addiction management services, including
drug substitution and harm reduction.
In summary, our results suggest that the implementation of the
revised IAS-USA guidelines for use of HAART in adults can have
a dramatic impact not just on the health of HIV infected
individuals but also on the spread of HIV. These results provide
powerful additional evidence regarding the need to ensure that
individuals in medical need of HAART can have access to this
lifesaving intervention for their own benefit, as well as, a way to
curb the growth of the epidemic. While implementing the revised
IAS-USA guidelines for use of HAART in adults may be
associated with significant challenges, including up front costs,
our analysis demonstrates that this is highly cost-effective and cost-
averting within a decade.
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Table S1 Definition and value for the parameters in the
transmission model.
Found at: doi:10.1371/journal.pone.0010991.s001 (0.09 MB
DOC)
Figure S1 Distribution of HIV infected individuals in British
Columbia engaged and not engaged in care. Groups are defined as
follows: (1) individuals currently receiving HIV treatment and care
(N = 4379); (2) individuals who are currently engaged in care, who
now meet the eligibility to start HAART under the new guidelines
(N = 1602); (3) same as group 2, but for personal reasons, despite
being well adjusted in society and engaged in medical care, are
reluctant to initiate treatment (N = 600); (4) individuals who are
currently engaged in care, but yet do not meet the eligibility to
start HAART under the new guidelines (N = 798); (5) represents
the current deficit of individuals (not engaged in care) who should
be on treatment under the previous guidelines because their CD4
cell count is ,200 cells/mm3; (6) and (7) individuals not engaged
in care, who now meet the eligibility to start HAART under the
new guidelines because their CD4 cell count is ,350 cells/mm3
(N = 1036) or because they meet at least one of the other criteria
for therapy initiation (N = 1476); (8) individuals who are not
engaged in care, and do not meet the eligibility to start HAART
under the new guidelines (N = 342).
Found at: doi:10.1371/journal.pone.0010991.s002 (0.45 MB TIF)
Figure 3. Return on increased investment resulting from implementation of the Status Quo approach versus 50% and 75%
expansion scenarios (over 40 years).
doi:10.1371/journal.pone.0010991.g003
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